Lamivudine Treatment of renal rehabilitation hepatitis B virus associated glomerulonephritis of 37 cases observed.docVIP

 PAGE \* MERGEFORMAT 8 Lamivudine Treatment of renal rehabilitation hepatitis B virus associated glomerulonephritis of 37 cases observed [Keywords:] Renal rehabilitation soup, lamivudine, hepatitis B virus associated glomerulonephritis Hepatitis B virus associated glomerulonephritis (HBV-GN) is the hepatitis B virus invades the human body, directly or indirectly, to produce a large number of hepatitis B virus surface antigen and immune complex deposition in glomeruli and the adsorption-induced glomerulonephritis, There is no definite therapy. author antiviral medicine, on the basis of liver side with self Rehabilitation Renal Treatment of the disease, and achieved good effect. are reported below. 1 Materials and Methods 1.1 Diagnostic criteria Selected cases for the March 2003 -2007 our hospital in March of HBV-GN 73 patients. Diagnosis meet in Beijing in 1989, “Hepatitis B virus associated glomerulonephritis seminar on the” [1] proposed the diagnosis of criteria: ① serum hepatitis B virus antigen positive, ② suffering from glomerulonephritis and may rule out other secondary glomerulonephritis, ③ renal biopsy in the detection of hepatitis B virus antigens. 1.2 General Information All patients underwent renal biopsy, of which 34 cases of membranous nephropathy, mesangial proliferative glomerulonephritis, 18 cases of mesangial proliferative glomerulonephritis in 15 cases, three cases of focal segmental glomerular sclerosis , glomerulosclerosis in 3 cases. by visiting randomly divided into 2 groups. the treatment group 37 group, 26 males and 11 females, aged 16 to 54 years (mean 27.2 + -7.3 years). the control group 36 cases, 24 males and 12 females, aged 17 to 53 years (mean 29.4 + -9.8 years) .2 patients gender, age, duration and treatment before the main symptoms, signs and laboratory test results of no difference between statistically significant (Pgt; 0.05), comparable. 1.3 Treatment Tablets in patients with oral lamivudine group